PARAMETERS OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN PATIENTS WITH HYPERTENSION DISEASE WITH CONCOMITANT TYPE 2 DIABETES

Abstract

The aim: To study the parameters of the left ventricular (LV) diastolic function in patients with HT with concomitant T2DM and without it before and after complex treatment with the inclusion of Eplerenone 50 mg per day and Trimetazidine 80 mg per day during 3 months. Materials and methods: The study included 50 patients, aged 45–54 years (mean age 51.3±1.5 years), women – 24 and men 26 with HT stage II. All patients were divided into 2 groups: 1 group (n=25) – patients with HT stage II (HbA1c level of 5.01±0.13%) and 2 group (n=25) – patients with HT stage II and concomitant T2DM (HbA1c level of 7.6±0.34%). The control group consisted of 20 healthy individuals (HbA1c level of 4.68±0.49%). Results: When analyzing the findings on left atrial volume index (LAVI), the highest indicators were observed in patients with HT with T2DM, but slightly lower in HT, and even lower in the control group, but the differences at this stage were not significant. This suggests that functional changes in cardiomyocyte kinetics, which develop in patients with comorbid pathology and are caused by metabolic and hemodynamic disorders, can progress steadily. Conclusions: After a three-month course of treatment with Eplerenone and Trimetazidine, the rate of myocardial relaxation in diastole likely increased in both groups of those examined. The prescribed treatment with Eplerenone and Trimetazidine has led to a decrease in the rate of progression of heart failure and a reduction in cardiovascular risks.